Compare Aon PLC (AON) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aon PLC vs Crispr Therapeutics AG — how do they compare? Aon PLC trades at $356.48 (market cap $75.61B), while Crispr Therapeutics AG trades at $53.96 (market cap $5.23B). The key difference: Aon PLC is far larger — about 14.5× Crispr Therapeutics AG's market cap, and Aon PLC pays a 0.92% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AON | CRSP | |
|---|---|---|
Market Cap | $75.61B | $5.23B |
Sector | Financials | Health |
52-Week High | $381.26 | $76.78 |
52-Week Low | $308.22 | $44.34 |
Enterprise Value | $90.22B | $3.65B |
Dividend Yield | 0.92% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
